Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.37 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 10/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395361 | 0.91 | PDE4D (0.38) | PDE4DLTC4SPDE4APDE4BPDE4C | |
| SCHEMBL985445 | 0.81 | PDE4A (0.49) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8007015 | 0.76 | PDE4D (0.47) | PDE4DLTC4SPDE4APDE4BPDE4C | |
| SCHEMBL987046 | 0.72 | PDE4A (0.51) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL17300559 | 0.71 | PDE4A (0.52) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL985446 | 0.71 | PDE4A (0.50) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1164704 | 0.71 | PDE4A (0.49) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6879299 | 0.69 | PDE4A (0.48) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1011391 | 0.69 | L3MBTL1 (0.44) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1008443 | 0.69 | PDE4D (0.47) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245038-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2018-11-07 | — | — | EP | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2245038-A1 | NEW MACROLIDES AND THEIR USE | Basilea Pharmaceutica AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | PDE4D 6/4885LTC4S 117/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.